- Home
- NOTV vs SVII Comparison
NOTV vs SVII Comparison
Compare NOTV & SVII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NOTV
- SVII
- Stock Information
- Founded
- NOTV 1974
- SVII 2021
- Country
- NOTV United States
- SVII United States
- Employees
- NOTV N/A
- SVII N/A
- Industry
- NOTV Biotechnology: Pharmaceutical Preparations
- SVII Blank Checks
- Sector
- NOTV Health Care
- SVII Finance
- Exchange
- NOTV Nasdaq
- SVII Nasdaq
- Market Cap
- NOTV 137.5M
- SVII 113.1M
- IPO Year
- NOTV 1997
- SVII 2022
- Fundamental
- Price
- NOTV $2.71
- SVII $11.77
- Analyst Decision
- NOTV Strong Buy
- SVII
- Analyst Count
- NOTV 1
- SVII 0
- Target Price
- NOTV $5.00
- SVII N/A
- AVG Volume (30 Days)
- NOTV 595.3K
- SVII 11.9K
- Earning Date
- NOTV 05-07-2025
- SVII 01-01-0001
- Dividend Yield
- NOTV N/A
- SVII N/A
- EPS Growth
- NOTV N/A
- SVII N/A
- EPS
- NOTV N/A
- SVII 0.33
- Revenue
- NOTV $480,402,000.00
- SVII N/A
- Revenue This Year
- NOTV $5.57
- SVII N/A
- Revenue Next Year
- NOTV $5.23
- SVII N/A
- P/E Ratio
- NOTV N/A
- SVII $35.93
- Revenue Growth
- NOTV N/A
- SVII N/A
- 52 Week Low
- NOTV $1.15
- SVII $11.06
- 52 Week High
- NOTV $6.48
- SVII $11.90
- Technical
- Relative Strength Index (RSI)
- NOTV 60.76
- SVII 70.91
- Support Level
- NOTV $1.96
- SVII $11.67
- Resistance Level
- NOTV $2.96
- SVII $11.90
- Average True Range (ATR)
- NOTV 0.24
- SVII 0.05
- MACD
- NOTV 0.08
- SVII 0.00
- Stochastic Oscillator
- NOTV 75.00
- SVII 49.85
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.
About SVII Spring Valley Acquisition Corp. II
Spring Valley Acquisition Corp II is a blank check company.